Shanghai Bovax Biotechnology Co., Ltd. Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2016
NCT03085381
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Chongqing Bovax Biopharmaceutical Co., Ltd. | Shanghai Bovax Biotechnology Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Condylomata Acuminata (Phase 3)

Papillomavirus Infections (Phase 1)

Vaginal Neoplasms (Phase 3)

Vulvar Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 2